• Here we studied GLUT targeted nanomedicines as a new

  2022-03-14

  

  Here, we studied GLUT1-targeted nanomedicines as a new strategy directed to overcome vascular barrier, enhancing delivery and efficacy in solid tumors. These nanomedicines were prepared by controlled installation of glucose on polymeric micelles incorporating the antitumor agent cisplatin, which is

• We and others have previously reported that neurons

  2022-03-14

  

  We and others have previously reported that neurons generated from iPSCs with genetic forms of AD recapitulate aspects of the disease, including increased Aβ peptide production in trisomy 21 and APP duplication neurons (Moore et al., 2015, Israel et al., 2012) and increased production of longer form

• In summary two new flexible amine functionalized quinolinium

  2022-03-14

  

  In summary, two new flexible amine-functionalized quinolinium derivatives with far-red region emitting were prepared. The shorter-chain fatty amine side chain in the scaffold of was found to be a more promising G-quadruplex DNA fluorescent probe, suggesting the amine side group plays an important r

• All of the abovementioned effects of PUFAs

  2022-03-14

  

  All of the abovementioned effects of PUFAs signal their involvement in a cellular phenotype switching phenomenon, which is increasingly recognized as a potential target for future pharmacotherapies of atherosclerosis, especially for individuals who do not respond to the classical lipid-lowering stra

• Despite their undisputed importance however FPR receptors ar

  2022-03-14

  

  Despite their undisputed importance, however, FPR receptors are not in the limelight of GPCR-related research (for review [12] and references therein). We, therefore, draw attention to this GPCR receptor family, in order to re-initiate FPR-related research, particularly in the light of biased agonis

• br STAR Methods br Acknowledgments We would like to

  2022-03-14

  

  STAR★Methods Acknowledgments We would like to thank V. Gladyshev (Harvard), H. Kornblum (UCLA), L. Greene (Columbia), and J. Baraban (Johns Hopkins) for constructive comments to the project and manuscript. We thank L. Gross and A. Kumar for assistance with editing. We thank L.M. Gerber and Z.

• br Acknowledgements The authors have

  2022-03-14

  

  Acknowledgements The authors have no ethical conflicts to disclose. The authors have no conflicts of interest to declare. This work was funded by the Research Council of Lithuania. Introduction This paper studies whether there is a causal influence of the risk-taking incentives provided by op

• In our cohort each patient had a median

  2022-03-14

  

  In our cohort, each patient had a median of 2 Anti-FXa measurements performed daily and a median of 1 infusion rate change daily to maintain therapeutic unfractionated heparin levels. Previously, several studies have documented that APTT-based protocols lead to more fluctuations in comparison with A

• br Anti Factor Xa methods

  2022-03-14

  

  Anti-Factor Xa methods for DiXaIs measurement in plasma Concerning Anti-Factor Xa methods, there is an excellent correlation between the 1-stage and 2-stage Anti-assays as shown in Fig. 6, and the concentrations measured are very similar with all methods. These methods and the DiXaI concentration

• Similar to in vitro data in vivo studies have also

  2022-03-14

  

  Similar to in vitro data, in vivo studies have also revealed modulation of TLR4-induced inflammatory responses by AEA. The proposed AEA reuptake inhibitor AM404 has been shown to attenuate TLR4-induced increases in plasma levels of IL-6 and IL-1β, the latter effect mediated by CB1 receptor activatio

• br Acknowledgments The breast cancer laboratory

  2022-03-14

  

  Acknowledgments The breast cancer laboratory is supported by the Australian National Health and Medical Research Council (NHMRC) grants no. 1016701, no. 1024852, no. 1086727; NHMRC IRIISS; the Victorian State Government through VCA funding of the Victorian Breast Cancer Research Consortium and Op

• GSK dimethylpiperidin yl butoxy phenyl piperidine carbonyl

  2022-03-14

  

  GSK-835726 (3-[4-[4-[4-[4-(3,3-dimethylpiperidin-1-yl)butoxy]phenyl]piperidine-1-carbonyl]naphthalen-1-yl]propanoic acid) is a dual H1/H3 receptor antagonist with the potential to be used in allergic rhinitis. Likewise GSK-1004723, the drug-likeness criteria have not been passed by this drug candida

• 2188 The cytotoxicity of these compounds against

  2022-03-14

  

  The cytotoxicity of these compounds against Hep3B cells was assessed using the MTT assay. As shown in , compounds in series and (except ), which retained the carboxyl at C-17, showed no appreciable cytotoxic activity (IC > 100 μM), whereas compounds in series (except ,) were modestly cytotoxic, i

• Compound containing dimethylglutarimide P cap P propyl

  2022-03-14

  

  Compound containing, dimethylglutarimide P-cap, P propyl group, α-methylbenzyl urea resulted in inhibitor with much improved binding (=0.064μM) and EC=0.3μM. This was an aza-peptide analog with an EC comparable to our first generation clinical candidate . Analog was evaluated for its selectivity

• br Methods br Results br

  2022-03-14

  

  Methods Results Discussion The aim of this study was to investigate whether serum lectin-binding activity is associated with development of HCC in HCV-positive individuals. Using ELISA-based assays of lectin-binding activity, we demonstrated that both age and gender influence the circulatin

14770 records 418/985 page Previous Next First page 上5页 416417418419420 下5页 Last page